2026-02-04 19:06:30,270 - replication - DEBUG - [core.utils] File logging configured: ./data/original/8/python/_log/extract.log
2026-02-04 19:06:30,270 - replication - INFO - Running Stage 1: original study extraction
2026-02-04 19:09:09,199 - replication - INFO - === GENERATED PROMPT (Stage 1) ===
You are an information extraction assistant tasked with filling out a structured JSON template based on research documents.

You will be provided with:
1. A JSON template where each key contains a description of what is expected
2. The original paper manuscript (original_paper.pdf)
3. Initial details file (initial_details_easy.txt) containing:
   - Claim statement (use this directly, do not extract from paper)
   - Hypotheses (use these directly, do not extract from paper)

Your goal is to:
- For 'claim.statement' field: Use the exact statement from initial_details_easy.txt
- For 'hypotheses' field: Use the exact list from initial_details_easy.txt
- For all other fields: Extract content only from original_paper.pdf
- Leave fields as `not stated` if information isn't found in the designated source

Output Requirements:
- Return a valid JSON object only.
- Do NOT wrap the output in markdown (no ```json).
- Do NOT include extra text, commentary, or notes.

Begin extraction using the provided schema below and the file contents. Ensure accuracy and completeness.
- Strictly use provided sources as specified.

Here is the JSON template, and its values represent descriptions of what is expected to be stored in each key:

{
  "original_study": {
    "claim": {
      "hypotheses": "A testable hypothesis based on the claim",
      "hypotheses_location": "Specific location where the hypotheses is stated in the original paper",
      "statement": "The main claim made by the original study that matches the claim given as an input.",
      "statement_location": "Specific location where the claim is stated in the original paper.",
      "study_type": "Type of study (Experimental, Observational, Meta-Analysis)"
    },
    "data": {
      "source": "Data Source (e.g., survey, database)",
      "wave_or_subset": "Specific waves or subsets (if applicable)",
      "sample_size": "Sample size of the selected data (if applicable)",
      "unit_of_analysis": "Unit of analysis (e.g., individual, household)",
      "access_details": "Access details (e.g., restrictions, request process)",
      "notes": "Any additional information or caveats (e.g., encoding issues, nested structure, missing metadata, unusual column formats)"
    },
    "method": {
      "description": "Narrative summary of how the study was conducted.",
      "steps": "Ordered list of procedural steps to reproduce the study.",
      "models": "Models or statistical approach (e.g., regression type)",
      "outcome_variable": "Dependent/outcome variable measured or analyzed",
      "independent_variables": "Primary variables expected to influence the outcome",
      "control_variables": "Variables controlled for in the analysis",
      "tools_software": "Tools or software specifics (e.g., mentions of R, Python, packages)"
    },
    "results": {
      "summary": "Narrative summary of the main results or findings from the original study.",
      "numerical_results": [
        {
          "outcome_name": "Name or label of the outcome (e.g., 'test_score', 'conversion_rate')",
          "value": "Numeric result value (e.g., 0.45)",
          "unit": "Optional unit of measurement (e.g., %, points, ms)",
          "effect_size": "Optional effect size (e.g., Cohen's d, odds ratio)",
          "confidence_interval": {
            "lower": "Lower bound (e.g., 0.32)",
            "upper": "Upper bound (e.g., 0.58)",
            "level": "Confidence level, e.g., 95"
          },
          "p_value": "Optional p-value associated with the result (e.g., 0.001)",
          "statistical_significance": "Boolean indicating if result is statistically significant",
          "direction": "Qualitative direction of the effect (positive, negative, or null) based on the sign and magnitude of the reported result."
        }
      ]
    },
    "metadata": {
      "original_paper_id": "DOI or unique identifier.",
      "original_paper_title": "Title of the original paper.",
      "original_paper_code": "Link to the original study's codebase.",
      "original_paper_data": "Link to the original study's dataset(s)."
    }
  }
}

Please return only a completed JSON object appropriate for this stage.
2026-02-04 19:09:09,200 - replication - INFO - 

=== GENERATED MESSAGE (Stage 1) ===
Extract stage 1 (original study) information.

You are tasked with extracting structured information from the following text based on the given instructions.

=== START OF FILE CONTENT ===

---
**original_paper.pdf**
--- PDF SUMMARY (Document was 38 pages long) ---
The document was too long to read directly, so here is a detailed summary of all sections:

The paper investigates the trade-off between increasing access and targeting when subsidizing antimalarial drugs, specifically artemisinin combination therapies (ACTs), in Kenya. This study evaluates the effectiveness of price subsidies and the introduction of rapid diagnostic tests (RDTs) in targeting ACTs to malaria-positive patients. The study used a randomized controlled trial involving over 2,700 households in Western Kenya, introducing random variations in access to subsidized ACTs and RDTs sold through local drug shops.

Key methodologies and findings include:

1. **Efficacy of ACT Subsidies**: 
   - A 92% subsidy on ACTs significantly increased access, doubling the treatment rate from 19% to 41%. However, only 56% of these ACTs went to malaria-positive individuals, indicating poor targeting.
   - The over-treatment issue was prominent in teens and adults aged 14 and over, among whom only 21% of those taking subsidized ACTs had malaria.

2. **Subsidy Levels**: 
   - The study varied the subsidy levels from 92% to 80%. At lower subsidy levels, targeting improved significantly, with the share of subsidized ACTs going to malaria-positive patients rising to 75%.
   - The reduction in subsidy led to a decline in adult dose purchases, suggesting that adults choose the cheapest antimalarial when uncertain about the illness cause. However, demand for ACTs for children remained unchanged across subsidy levels.

3. **Rapid Diagnostic Tests (RDTs)**: 
   - When RDTs were made available at an 85% or more subsidy, the rate of testing for malaria doubled. 
   - Despite increased testing, over half of the patients who tested negative still opted to take a subsidized ACT, suggesting limited immediate effectiveness of RDTs in reducing over-treatment.

Overall, the study concludes that while price subsidies effectively increase access to antimalarials, they result in significant over-treatment among adults. The introduction of RDTs improved testing but did not immediately solve the over-treatment issue. The study suggests that compliance with negative test results might improve over time as trust in RDTs increases.

The text discusses the impact of the AMFm (Affordable Medicines Facility for malaria) initiative, which aims to reduce the cost and increase the availability of ACTs (artemisinin-based combination therapies) in retail sectors in developing countries, particularly in Africa. The AMFm program provided a 95% subsidy to pharmaceutical wholesalers to achieve this goal, but faced criticism for its high cost and questionable impact on saving lives or delaying drug resistance.

Key Findings and Methodologies:
1. The study highlights the challenges of accessing effective malaria treatment in developing countries, especially among children under five, who are most vulnerable to malaria.
2. It evaluates the AMFm's effectiveness in reaching the malaria-positive poor without significantly reducing public sector care use.
3. The study emphasizes the trade-off between expanding access (potentially saving lives) and over-treatment (increasing costs and resistance risk).
4. A theoretical framework models treatment-seeking behavior, examining under-treatment (UT) and over-treatment (OT) of malaria episodes through access (A) and targeting (T) metrics, considering overall malaria prevalence (\(\Pi\)).

Results:
- The AMFm subsidy significantly expanded access for malaria-positive individuals, especially among the poor.
- The program did not meaningfully crowd out public sector care.
- High levels of over-treatment were observed, suggesting excessive ACT use by individuals not truly malaria-positive.
- Modestly reducing subsidy levels could maintain AMFm benefits while reducing over-treatment and costs.

Conclusions:
- The study suggests a careful balance in subsidy levels to optimize benefits and costs.
- The results are significant for policy-making in designing malaria interventions, with potential applicability across East Africa due to similar treatment-seeking environments.
- Raises concerns about under-diagnosis and over-treatment, contributing to global health care costs.
- Emphasizes the importance of understanding treatment-seeking behavior in resource-constrained settings for effective health interventions. 

Overall, the research highlights the complexities of pricing, targeting, and behavioral responses in the deployment of health subsidies and their impact on malaria treatment in developing countries.

The text discusses a study on household treatment choices for suspected malaria cases in Western Kenya, considering the economic implications of subsidizing anti-malarial treatments and rapid diagnostic tests (RDTs). The study assumes households accurately assess their probability of having malaria, denoted as π, and the decision to seek different treatments depends on this probability. The utility of taking a particular action, V\_a(π), is a function of the malaria probability and includes considerations of cost and effectiveness of treatment or non-treatment options, denoted as actions h (health center), s (ACT at drug shop), and n (doing nothing or non-ACT medication).

Panel A of Figure 1 illustrates a scenario where buying an ACT is preferred at high malaria probabilities, visiting a health center is preferred at moderate probabilities, and taking other actions at low probabilities.

The paper explores the impact of two subsidy types:

**ACT Subsidy**: 
- Reduces the cost of ACTs at drug shops, potentially increasing access but decreasing targeting. Malaria-negative individuals previously not receiving ACTs may now receive them due to the reduced cost. Targeting worsens if the subsidy primarily benefits those who would have accessed ACTs regardless.

**RDT Subsidy**: 
- Adds a diagnostic option at drug shops, potentially improving targeting by helping differentiate between malaria and non-malaria cases. The subsidy reduces over-treatment for individuals who comply with results but may increase it if compliance is low.

The study emphasizes the importance of understanding distributional impacts of subsidies, i.e., whether they help high-malaria-probability populations who previously lacked access. The experimental design involved four drug shops in Western Kenya, with 2,789 households receiving vouchers for ACTs and RDTs. The baseline survey revealed the majority of these households had previously patronized the participating drug shops. 

Ultimately, the study seeks detailed data on illness and treatment-seeking behaviors to evaluate the effects of different subsidy policies on treatment access and targeting. The field experiment was designed to achieve this by collecting data on households' treatment choices and vouchers' influence at drug shops.

The study explores the impact of subsidies for antimalarial treatments, focusing on Artemisinin-based Combination Therapies (ACTs) and Rapid Diagnostic Tests (RDTs) within a randomized experimental design. Conducted in rural Kenyan areas, the study divided households into four groups: no subsidy (control), ACT subsidy only, ACT plus RDT subsidy, and varying subsidy levels (92%, 88%, and 80%).

**Methodology:**
1. **Random Assignment:** Households were randomly allocated to receive either unsubsidized or subsidized ACTs and RDTs. 
2. **ACT and RDT Subsidy Levels:** Within subsidized groups, participants received varying subsidy levels for ACTs corresponding to $0.50, $0.75, and $1.25 per adult dose, aligned with the Kenyan government's target prices.
3. **Surprise RDT Offers:** Households were randomly selected to receive surprise RDT offers to evaluate malaria positivity among ACT users without pre-selection biases.
4. **RDT Subsidy Variations:** In the ACT+RDT groups, RDTs were offered for free, for $0.19, or at a refundable price if the test was positive and an ACT was purchased.

**Key Findings:**
- **Subsidy Effectiveness:** Substantial take-up of ACTs was observed with subsidies. 
- **Malaria Positivity Rates:** A high percentage (93%) of participants consented to the surprise RDT, providing data on malaria status alongside treatment access.
- **RDT Willingness to Pay:** Few differences were found in RDT uptake across different price points, indicating low sensitivity to RDT pricing in decision-making.
- **Household Characteristics:** The study maintained balanced baseline characteristics across groups, with typical households being 1.7 km from drug shops and 6.6 km from health facilities.

**Results:**
- The introduction of ACT and RDT subsidies increased the accessibility and diagnosis accuracy of malaria treatment.
- The study suggested an equilibrium between subsidy levels and accessibility, with implications for public health policy in balancing affordability with healthcare access.

**Conclusions:**
The research highlights potential policy implications for managing malaria treatment through subsidized pricing, particularly in remote areas where health facilities are sparse. The outcomes stress the importance of diagnostic testing in conjunction with treatment to reduce over-treatment while increasing effectiveness. The findings are robust after adjusting for false discovery rates, suggesting that subsidized pricing strategies can significantly affect public health outcomes.

The technical paper evaluates the impact of retail sector Artemisinin-based Combination Therapy (ACT) subsidies on malaria treatment decisions, focusing on two main outcomes—under-treatment (UT) and over-treatment (OT). 

Key Methodologies:
1. Data Sources: 
   - Administrative data from drug shop transactions, capturing medicine purchases, symptoms, patient characteristics, and malaria status if a Rapid Diagnostic Test (RDT) was utilized.
   - An endline survey capturing illness episodes, symptoms, treatment sought, and medications purchased.
   - A symptoms database assessing illness-specific characteristics and correlating them with malaria positivity using RDTs.

2. Analysis Approach:
   - Conducted regression analyses to estimate the impacts of ACT subsidies on two indirect outcomes: access (A) and targeting (T). 
   - Controlled for age due to its significant correlation with malaria positivity rates.
   - Assessed predicted malaria positivity by using a symptoms database and corroborated this proxy with actual test results, achieving a correlation of 0.48.

Specific Metrics & Results:
- Average treatment cost was $1.63 per episode.
- Malaria positivity was highest among children under five (54%) compared to adults aged 14 and above (14%).
- The study found significant statistical relationships (p < 0.001) indicating households possess private information influencing treatment-seeking behavior based on perceived malaria risk.
- Regression analysis showed impacts on ACT access and treatment-seeking behavior, but the document specifics on coefficients or statistical significance from the regression analyses were not detailed in the provided text.

Conclusions:
1. Age is a critical predictor of malaria positivity and significantly affects treatment-seeking behavior for ACTs.
2. Retail sector ACT subsidies influence treatment access and targeting, albeit indirectly, which could affect both under-treatment and over-treatment of malaria.
3. The framework suggests potential benefits in tailoring ACT and RDT subsidies to be more cost-effective, especially targeting populations based on age due to differential risk levels.
4. The symptoms database is a reliable proxy for predicting real malaria status, informing better-targeted interventions.

While the document details the analytical framework and empirical results regarding treatment-seeking behavior and subsidy impacts, it calls for considering age as a pivotal factor in malaria management strategies.

The paper investigates the impact of subsidies for Artemisinin-based Combination Therapies (ACT) on treatment-seeking behavior and access to ACTs. The study utilizes a stratified field experiment design and leverages data from first illness episodes reported by households. The analysis is divided into two panels. Panel A pools data from three subsidy levels, and Panel B evaluates each subsidy level (92%, 88%, and 80%) separately, comparing them to a control group that received no subsidy.

Key methodologies include analyzing the impact of subsidies on several outcomes: taking ACT, location of ACT acquisition (drug shop vs. health center), visiting drug shops or health centers, and obtaining malaria tests or antibiotics. Results are based on regression analyses controlling for household characteristics and clustered standard errors at the household level.

### Key Findings:
- **ACT Access:** In the control group, only 19% of illness episodes were treated with ACTs, despite being supposed to be freely available at health centers. All subsidy levels significantly increased ACT access by 16-23 percentage points, translating to an 85-118% increase over the control.
- **Treatment Seeking Behavior:** Subsidies increased drug shop visits by 16-17 percentage points and reduced the proportion of households seeking no care by 9-11 percentage points. The crowding out of health center visits was observed, but there was no decrease in malaria testing.
- **Targeting:** The study analyzed the targeting of ACTs using drug shop data and surprise Rapid Diagnostic Tests (RDTs). Only 56% of patients using a 92% subsidy were malaria-positive, whereas targeting improved significantly at lower subsidy levels (88% and 80% subsidies), with positivity rates increasing by 18-19 percentage points.
- **Subsidy Impact:** Despite large increases in ACT access across all subsidy levels, differences among subsidy levels were not substantial in most outcomes, and no significant difference was found between subsidy levels in improving targeting accuracy.

The study concludes that wholesale ACT subsidies significantly improve access to ACTs and influence treatment-seeking behavior, particularly in increasing drug shop visits and reducing antibiotic use. The effectiveness of targeting was better at lower subsidy levels, suggesting potential for refinement in subsidy design to enhance targeting while maintaining accessibility. The study's conclusions are supported by administrative data cross-checked with end-line survey reports, ensuring the credibility of self-reported household data.

The document explores the effects of antimalarial treatment subsidies and rapid diagnostic tests (RDTs) on targeting appropriate treatment. It considers how different subsidy levels for Artemisinin-based Combination Therapies (ACTs) affect the likelihood of malaria-positive patients receiving treatment. 

Key Methodologies:
1. The study analyzes ACT targeting by comparing predicted and actual positivity among ACT receivers, with a focus on endline data for first illness episodes in households not surprised with RDT results.
2. It examines two mechanisms through which subsidy levels might alter the composition of ACT users: changes in which households seek treatment and within-household decision-making based on illness severity and patient demographics.

Specific Metrics and Results:
1. The analysis shows that raising ACT prices leads to a preference for treating individuals more likely to be malaria-positive, particularly children. When subsidies decrease from 92% to 80%, there's a notable reallocation from adult to child patients.
2. Statistical significance is employed to emphasize results, where a price drop to 80% subsidy lowers adult ACT purchases by 16 percentage points (41% decrease).
3. Table 5 evaluates the impact of RDT subsidies, revealing that RDT usage significantly increases diagnostic testing (21.6% point increase) but does not change the location of care sought.

Conclusions:
1. Higher ACT prices (lower subsidies) discourage non-malaria-positive adults from purchasing ACTs but do not significantly restrict access for children who need these treatments most.
2. Even with lower subsidies, 25% of ACTs are administered to confirmed malaria-negative patients, highlighting a need for better diagnostic tool availability.
3. The introduction of an RDT subsidy increases testing without altering care-seeking locations, suggesting limited perceived value to RDTs absent of ACT price modulation.
4. Overall, while pricing adjustments influence treatment allocation effectively, access improvement for diagnostics remains essential to optimize subsidy impacts.

**Methodologies:**
The study examines the impact of Rapid Diagnostic Test (RDT) subsidies on antimalarial treatment, focusing on how these subsidies influence the targeting and utilization of subsidized Artemisinin-based Combination Therapies (ACTs). The analysis uses regression models to explore the interaction between different subsidy levels for ACTs (80%, 88%, and 92%) and the presence of an RDT subsidy.

**Specific Metrics:**
- Changes in malaria testing rates post-RDT subsidy were measured, showing an increase between 15-26 percentage points.
- The redemption rate of RDT vouchers at drug shops was approximately 80%.
- The study tracked ACT use post-negative and positive RDT results, observing compliance rates based on subsidy levels.
- The effects of RDT subsidies on the likelihood of malaria positivity among ACT takers were assessed.

**Key Results:**
- The RDT subsidy led to a significant increase in malaria testing without impacting overall ACT or antibiotic use.
- There was a positive selection in treatment-seeking behavior, particularly noticeable under the highest (92%) ACT subsidy level.
- The RDT subsidy increased malaria positivity by eight percentage points among those taking ACTs; notably, RDT targeting benefits were highest with the most subsidized ACTs.
- Compliance with RDT results was partial, with approximately half of the patients still taking ACTs despite negative test results, indicating cautiousness in trusting RDT outcomes.
- Hoarding of ACTs did not appear to be significant, supported by the timing and extent of voucher redemptions.

**Conclusions:**
- RDT subsidies markedly increased malaria testing rates but had limited effect on enhancing ACT targeting, especially when subsidies on ACTs were high.
- RDTs improved the targeting of subsidized ACTs mainly through positive selection into drug shops, particularly under higher subsidy scenarios.
- The study suggests that despite limited short-term impacts on ACT targeting, RDTs can potentially improve targeting effectiveness over time as households become more familiar with test reliability.
- The findings indicate a cautious approach by households toward RDTs, partly due to historical reliance on less accurate diagnostics and concern over false negatives.

Overall, while RDT subsidies effectively increase testing, the substantial reliance on ACTs remains unchanged, highlighting potential areas for intervention in education or marketing to improve RDT trust and compliance.

The study investigates the impact of varying subsidy levels for antimalarial treatment, focusing on the share taking Artemisinin-based Combination Therapy (ACT) and targeting effectiveness at drug shops and health centers. Key metrics include:

1. Share taking ACT overall and at different locations: Without subsidies, the total share taking ACT is 19%, which increases to 41.5% with an 80% ACT subsidy. The share taking ACT at drug shops increases significantly from 7.1% to 32%.
2. Targeting effectiveness at drug shops decreases from perfect targeting to 56.3% with some subsidies but remains relatively high (around 80%) as subsidies increase.
3. Over-treatment and under-treatment rates are tracked under different assumptions of targeting at health centers (medium, high, and low). At medium targeting, over-treatment decreases from 26.6% to 4.8%, while under-treatment decreases from 58.3% to 20.7%.
4. Cost and welfare analysis indicates an 80% ACT subsidy is more cost-effective than the typical subsidies under the Affordable Medicines Facility-malaria (AMFm) due to reduced over- and under-treatment.
5. The addition of a rapid diagnostic test (RDT) subsidy does not seem cost-effective short-term, as the targeting improvement is negligible compared to an ACT-only subsidy despite additional costs (around $1 per test).

The study suggests that while ACT subsidies effectively improve targeting and access, RDTs still pose potential benefits by increasing the appropriate treatment of non-malaria illnesses. The overall conclusion is that the 80% subsidy provides more cost-effective malaria treatment, balancing access and accurate targeting, though long-term RDT benefits require further research.

Regarding welfare, the 80% subsidy is considered optimal. It maximizes malaria-positive ACT treatment while minimizing costs and the unnecessary treatment of non-malaria cases, assuming no severe side effects from over-treatment. Although the study focuses on Kenya, the treatment-seeking environment is comparable to other regions with high malaria burdens, suggesting broader applicability of the findings.

The technical document evaluates the Affordable Medicines Facility – malaria (AMFm) subsidy program's effectiveness and proposes recommendations for improving treatment targeting for malaria. Stocking data from surveys conducted in rural and small urban areas post-AMFm pilot phase in Kenya, Uganda, and Tanzania suggested that over-treatment was a significant issue—only 45% of patients taking Artemisinin-based Combination Therapies (ACTs) tested positive for malaria. This was close to the 56% targeting observed in an earlier study under a 92% subsidy scenario.

Key Methodologies:
- The study used household surveys consisting of over 2,700 households in malaria-endemic regions.
- Conducted analysis of demand for ACTs based on pricing and diagnosis.

Specific Metrics and Results:
- Over-treatment was common: 45% of patients using ACTs had a positive malaria diagnosis.
- Demand for ACTs was high with subsidies, but did not rise at unsubsidized prices, indicating the need for carefully structured subsidies.
- Price elasticity analysis indicated subsidies are necessary to increase ACT access, particularly among rural, poor populations.
- Higher ACT prices reduced inappropriate adult usage while maintaining child access, suggesting an approach for improving targeting.

Conclusions:
- Significant over-treatment with ACTs persists, requiring well-calibrated subsidy levels.
- Diagnostic testing demand is high when affordable, yet compliance with results needs improvement for effective targeting.
- Further research is needed into incentives for providers and effective use of Rapid Diagnostic Tests (RDTs) to solve diagnostic-related over-treatment problems.
- The study implies adjustments in the AMFm, such as integrating diagnostics with subsidies, could enhance performance without requiring hefty subsidies. 

The research stresses the delicate balance necessary between drug accessibility and misuse prevention, calling for innovative policy adjustments to optimize the malaria treatment landscape.

The text provided appears to be a list of references from a research document, highlighting various studies related to malaria and health economics. These references contain information on different methodologies, outcomes, and interventions related to malaria control and healthcare systems, particularly in developing countries.

Key methodologies and metrics discussed across these references include:

1. **Malaria Drug Shortages and Treatment Access**: The study by Kangwana et al. (2009) discusses failures in providing effective malaria treatment in Kenya due to drug shortages, emphasizing the need for better healthcare provisioning systems.

2. **Health Outcomes and Doctor Quality**: Leonard (2007, 2009) focuses on the role of selecting better doctors to improve health outcomes, utilizing social learning and assessing costs related to healthcare agency inefficiencies.

3. **Retail Distribution for Malaria Treatment**: Patouillard et al. (2010) review literature on the distribution chains within the retail sector for malaria treatment, which impacts accessibility to effective drugs.

4. **Drug Resistance**: Terlouw et al. (2003) and White (2004) address issues of increasing resistance to antimalarial drugs (Sulfadoxine-Pyrimethamine) in Kenya and overall antimalarial drug resistance.

5. **Micro-loans and Health Interventions**: Tarozzi et al. (2014) conduct a randomized controlled trial in India examining the impact of micro-loans and insecticide-treated bednets on malaria prevalence.

6. **Diagnostics in Malaria Control**: Perkins and Bell (2008) emphasize the critical role of diagnostics in effective malaria control, suggesting that accurate diagnostics can direct appropriate treatment.

7. **Subsidies and Targeting of Antimalarials**: Discussed in studies like those by Nichols and Zeckhauser (1982) and Olmstead and Zeckhauser (1999), focusing on economic models to optimize the targeting and pricing of health interventions.

The outcomes and conclusions from these references contribute to a comprehensive understanding of strategies to improve malaria treatment delivery and healthcare efficiency in developing regions. They highlight the importance of addressing drug resistance, enhancing healthcare worker quality, and leveraging economic incentives to widen access to effective malaria treatments. Additionally, they underline the necessity for reliable diagnostic systems and optimal resource allocation to address the challenges facing malaria control and healthcare in resource-limited settings.

=== CODE RELATED FILES ===

=== DATASET FILES ===
=== END OF FILE CONTENT ===
2026-02-04 19:09:40,843 - replication - INFO - Updated metadata for extract_stage_1 in ./data/original/8/python/metadata.json
